A three-gene panel related to CXCL16 can be used to predict the disease prognosis, and targeting CXCL16 may be a good therapeutic strategy for macrophage-enriched, advanced thyroid cancer. This evidence concerns the gene CXCL16 and thyroid gland carcinoma.